In its back-and-forth battle with Merck for supremacy of the next-gen pneumococcal vaccine market, Pfizer is looking for any edge it can get. Monday’s news that the drugmaker has begun testing its COVID-19 vaccine and 20-valent pneumococcal vaccine candidate together could provide exactly that advantage.
Pharmaceutical stocks often need just a single blockbuster drug to make their fortunes.
Though the definition varies, blockbuster drugs are those that generate annual sales of $1 billion or more. The biggest blockbuster drugs can even exceed $100 billion in lifetime sales.
All of the companies on this list have drugs in their pipelines which could eclipse the billion dollar revenue milestone.
A blockbuster drug may be enough to send a smaller company’s stock price skyrocketing. Yet, in a larger pharmaceutical firm, a succession of blockbuster drugs is necessary simply to keep prices stable. Investors should keep that in mind before buying into any of the equities on this list.
As the impeachment trial for former President Trump plays out, the pharmaceutical industry can thank itself for playing a role — albeit, a small one — in this unseemly national spectacle.
Why do I say that? Let’s connect some dots.
During the previous two election cycles, the industry donated more than $2.4 million to the Republican Attorneys General Association, which made campaign contributions to the Texas attorney general who filed a lawsuit challenging results from the presidential election in several states. The association also funded attorneys general from 11 other states who supported the effort.
German pharmaceutical giant Bayer announced Monday it will help a smaller German biomedical company, CureVac, produce its experimental COVID-19 vaccine, the latest drug maker to offer up manufacturing capacity as supplies fall behind demand worldwide.
At a virtual news conference hosted in Berlin Monday by Health Minister Jens Spahn, Bayer’s pharmaceutical chief, Stefan Oelrich, said the company expects to produce 160 million doses of CureVac’s experimental vaccine, which is currently in late-stage testing, in 2022.
Bayer and CureVac reached an agreement last month to work together on a vaccine. Oelrich said Bayer has experience and capacity to expand CureVac’s production capacity.
One of the most unequal places on the planet with lavish malls on the one side, overcrowded slums on the other, Hong Kong has seen its divide worsening during the first lockdown, brought about by the coronavirus pandemic. The government had locked down some 10,000 residents in the most popular area neighbouring the Jordan district for almost three weeks after infections surged. Officials said the cramped residential areas may have fuelling the outbreak and admitted the pain of residents living in such spaces with poorer ventilations under lockdown. Critics have blamed the government for allowing the conditions for an outbreak to fester and then imposing heavy-handed measures on a group that can least afford to bear them.
In his terrific book, The Great American Drug Deal, Peter Kolchinsky talks about one of the most common surgical procedures – hip replacements. There are over 400,000 such procedures done in the U.S. annually. In fact, given my age, I now have a handful of friends who have had at least one hip done. Hip replacement surgeries were first carried out in the 1940s and, while the methodology has improved, the procedure is essentially the same today and costs about $40,000 (not including extended nursing and rehabilitation). This surgery cost the U.S. healthcare system about $16 billion in 2019 – a figure that will undoubtedly continue to grow.
Mark Cuban is getting involved in generic drugs.
The Dallas Mavericks owner has attached his name to a company that will produce low-cost versions of expensive generic drugs. The Mark Cuban Cost Plus Drug Company pledges “to provide radical transparency” in how it prices its drugs.
The company will manufacture, distribute, and market its drugs to pharmacies and add a flat 15% margin to get wholesale prices.
The first drug to be produced is albendazole, an anti-parasitic pill that can retail for over $400 per tablet. The company plans to make and distribute the drug for about $13, charge $15 as a wholesale price and set a manufacturer’s suggested retail price of $20 per tablet, according to the company’s website.
As the nation struggles to scale up its COVID-19 immunization rollout, another vaccine in the works could soon help bridge the gap.
The two vaccines available now — one by Pfizer/BioNTech and another by Moderna — require two doses: a priming shot and then a booster three or four weeks later, depending on which company’s injection you get.
But another vaccine on the horizon — developed by Johnson & Johnson — would require only a single dose. It could be a game-changer for distribution, which continues to drag in New Jersey and beyond.
AM-Pharma has recruited first patients with Covid-19 infection and sepsis-associated acute kidney injury (SA-AKI) in an exploratory cohort of its phase III REVIVAL pivotal trial.
The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients with SA-AKI.
AM-Pharma will recruit up to 1,400 patients with SA-AKI in the main study population. The company will recruit up to 100 patients with moderate chronic kidney disease (CKD) and up to 100 patients with Covid-19 in two exploratory cohorts.
Pharma executives and trade groups joined the chorus of voices condemning the pro-Trump insurrection on Capitol Hill yesterday. Speaking up on social media and issuing statements against the mob chaos—as Congress worked to certify President-elect Joseph Biden’s election—industry reps went so far as to support a call to consider removing President Donald Trump from office.
- Here’s why 1,500 Pennsylvania nursing home workers are planning a one-day strike next week July 21, 2021
- The Untamed Rise Of Hospital Monopolies July 20, 2021
- Johnson & Johnson is recalling sunscreens due to low levels of benzene, a carcinogen July 15, 2021
- Lifestyle intervention program improves CV, mental health in obesity June 18, 2021
- OSHA issues long-delayed COVID-19 safety rules for healthcare workplaces June 14, 2021